Loading...
Please wait, while we are loading the content...
Similar Documents
Biomarkers in Prostate-Specific Membrane Antigen Theranostics
| Content Provider | MDPI |
|---|---|
| Author | Vlachostergios, Panagiotis Zachos, Ioannis Tzortzis, Vassilios |
| Copyright Year | 2021 |
| Description | Theranostics of prostate cancer (PC) represents a growing area of development of imaging agents and targeted radionuclide therapeutics against a major target, prostate specific membrane antigen (PSMA). In view of the encouraging efficacy from the use of$ ^{177}$Lu and other radionuclides in metastatic castration-resistant prostate cancer (mCRPC), it is becoming increasingly important to identify surrogate markers that can help predict which patients are more likely to respond and experience improved survival. This review discusses potential predictors of efficacy of PSMA-targeted radionuclide therapies (TRT) segregated in three major categories: imaging, clinical and molecular. |
| Starting Page | 1108 |
| e-ISSN | 20754418 |
| DOI | 10.3390/diagnostics11061108 |
| Journal | Diagnostics |
| Issue Number | 6 |
| Volume Number | 11 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-06-18 |
| Access Restriction | Open |
| Subject Keyword | Diagnostics Radiology, Nuclear Medicine and Imaging Prostate Specific Membrane Antigen Theranostics Radionuclide Therapies 177lu Biomarker Predictive Prognostic Psa Response Progression-free Survival Overall Survival Metastatic Castration-resistant Prostate Cancer |
| Content Type | Text |
| Resource Type | Article |
